Login to Your Account

Adimab Hooks GSK, Expands Biogen Alliance

By Marie Powers
Staff Writer

Friday, July 26, 2013

Despite the proliferation of biotech initial public offerings (IPO) this year – including two that priced yesterday (see the related story in this issue) – Adimab LLC is distinctly disinterested in the public markets. And the Lebanon, N.H., firm can well afford to remain private. Early Friday morning, the company disclosed two more in a string of lucrative deals that catapulted it to profitability just three years after its 2007 launch.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription